Skip to content Skip to footer

Our Journey

1981

➤ Journey starts as Seagull Laboratories. All founders quit comfortable jobs in MNC's and start gaining the trust of the medical fraternity.

1984

➤ Inception of Seagull Pharmaceuticals, to manufacture our brands in-house.

1991

➤ Launch of NVM tablet for managing neuropathy. Product is based on a unique concept and is an immediate success.

1998

➤ Company breaks the price barrier for nimesulide tablets. Nimprex treats fever at just 40 paise/tablet.

2006

➤ Seagull enters the niche but rapidly growing derma cosmetics segment.
➤ Introduce Biomane for alopecia, a unique product which combines biotin with zinc.
➤ Introduce Noswet anti-perspirant, another novel concept.

2007

➤ Company breaks the price barrier for levocetirizine tablets. Levotac treats allergies at just 50 paise/tablet.
➤ Revenue crosses 10 crores.

2010

➤ Introduce Superspas antacid gel - a unique composition based on UKMHRA guidelines. Product gets immediate acceptance and helps grow the Superspas franchise.
➤ Price barrier broken for levocetirizine with montelukast tablets with the launch of Levotac-M tablets at only 5.90/ tablet.

2011

➤ Revolutionise the migraine treatment market by introducing "Comig". Product gains immediate acceptance due to its unique composition.

2013

➤ Revenue crosses 20 crores.

2017

➤ Launch of CBcount tablet and syrup for patients with low platelets. Product is an immediate success because of its innovative composition which tackles all 5 challenges associated with dengue fever.
➤ Revenue crosses 40 crores

2019

➤ Introduce the "fruit-laxative" concept. Launch Outlet drops, a unique and natural solution for paediatric constipation.
➤ Introduce Penova-IBS - The only enteric coated softgel capsules of peppermint oil for IBS patients

2020

➤ Revenue crosses 50 crores

2021

➤ Recognised by The Economic Times and Statista amongst "Indias Growth Champions" .
➤ Recognised by The Financial Times amongst "High Growth Companies in Asia-Pacific".
➤ Revenue crosses 60 crores despite Covid lockdowns.
➤ Seagull becomes the first Pharma company to bring Amber, an AI-enabled chatbot, on board as our Chief Listening Officer.

2022

➤ Recognised by The Economic Times and Statista amongst "Indias Growth Champions"
➤ Recognised by The Financial Times amongst "High Growth Companies in Asia-Pacific".
➤ "Superspas" wins the "Perception that matters" Award from Pronto Consult.
➤ Launch of NVM-LC for patients of chronic fatigue. Product is an immediate success because of its innovative composition.
➤ Price barrier broken for bilastine with montelukast tablets with the launch of Alertac-M tablets at only 6.49/ tablet.
➤ Revenue crosses 80 crores

2023

➤ Seagull ties up with micro learning platform byteEdge, to provide learning on the go to our sales team.
➤ Recognised by The Economic Times and Statista amongst "Indias Growth Champions"  for the third successive year.
➤ Recognised by The Financial Times amongst "High Growth Companies in Asia-Pacific" for the third successive year.
➤ Further strengthen the Outlet franchise by introducing "Outlet" syrup for geriatric constipation
➤ Revenue crosses 90 crores

1981
timeline img

➤ Journey starts as Seagull Laboratories. All founders quit comfortable jobs in MNC's and start gaining the trust of the medical fraternity.

2011-jan-15
1984
timeline img

➤ Inception of Seagull Pharmaceuticals, to manufacture our brands in-house.

2011-jan-15
1991
timeline img

➤ Launch of NVM tablet for managing neuropathy. Product is based on a unique concept and is an immediate success.

2011-jan-15
1998
timeline img

➤ Company breaks the price barrier for nimesulide tablets. Nimprex treats fever at just 40 paise/tablet.

2011-jan-15
1999
timeline img

➤ Launch of Superspas tablet/ injection for abdominal pain. Product is based on a unique concept and is an immediate success.

2011-jan-15
2006
timeline img

➤ Seagull enters the niche but rapidly growing derma cosmetics segment.
➤ Introduce Biomane for alopecia, a unique product which combines biotin with zinc.
➤ Introduce Noswet anti-perspirant, another novel concept.

2011-jan-15
2007
timeline img

➤ Company breaks the price barrier for levocetirizine tablets. Levotac treats allergies at just 50 paise/tablet.
➤ Revenue crosses 10 crores.

2011-jan-15
2010
timeline img

➤ Introduce Superspas antacid gel - a unique composition based on UKMHRA guidelines. Product gets immediate acceptance and helps grow the Superspas franchise.
➤ Price barrier broken for levocetirizine with montelukast tablets with the launch of Levotac-M tablets at only 5.90/ tablet.

2011-jan-15
2011
timeline img

➤ Revolutionise the migraine treatment market by introducing "Comig". Product gains immediate acceptance due to its unique composition.

2011-jan-15
2013
timeline img

➤ Revenue crosses 20 crores.

2011-jan-15
2017
timeline img

➤ Launch of CBcount tablet and syrup for patients with low platelets. Product is an immediate success because of its innovative composition which tackles all 5 challenges associated with dengue fever.
➤ Revenue crosses 40 crores

2011-jan-15
2019
timeline img

➤ Introduce the "fruit-laxative" concept. Launch Outlet drops, a unique and natural solution for paediatric constipation.
➤ Introduce Penova-IBS - The only enteric coated softgel capsules of peppermint oil for IBS patients

2011-jan-15
2020
timeline img

➤ Revenue crosses 50 crores

2011-jan-15
2021
timeline img

➤ Recognised by The Economic Times and Statista amongst "Indias Growth Champions" .
➤ Recognised by The Financial Times amongst "High Growth Companies in Asia-Pacific".
➤ Revenue crosses 60 crores despite Covid lockdowns.
➤ Seagull becomes the first Pharma company to bring Amber, an AI-enabled chatbot, on board as our Chief Listening Officer.

2011-jan-15
2022
timeline img

➤ Recognised by The Economic Times and Statista amongst "Indias Growth Champions"
➤ Recognised by The Financial Times amongst "High Growth Companies in Asia-Pacific".
➤ "Superspas" wins the "Perception that matters" Award from Pronto Consult.
➤ Launch of NVM-LC for patients of chronic fatigue. Product is an immediate success because of its innovative composition.
➤ Price barrier broken for bilastine with montelukast tablets with the launch of Alertac-M tablets at only 6.49/ tablet.
➤ Revenue crosses 80 crores

2011-jan-15
2023
timeline img

➤ Seagull ties up with micro learning platform byteEdge, to provide learning on the go to our sales team.
➤ Recognised by The Economic Times and Statista amongst "Indias Growth Champions"  for the third successive year.
➤ Recognised by The Financial Times amongst "High Growth Companies in Asia-Pacific" for the third successive year.
➤ Further strengthen the Outlet franchise by introducing "Outlet" syrup for geriatric constipation
➤ Revenue crosses 90 crores

2011-jan-15